Amicus Therapeutics, Inc. (FOLD)
NASDAQ: FOLD · Real-Time Price · USD
14.25
0.00 (0.00%)
At close: Dec 29, 2025, 4:00 PM EST
14.26
+0.01 (0.07%)
After-hours: Dec 29, 2025, 5:55 PM EST
Amicus Therapeutics Employees
Amicus Therapeutics had 499 employees as of December 31, 2024. The number of employees decreased by 18 or -3.48% compared to the previous year.
Employees
499
Change (1Y)
-18
Growth (1Y)
-3.48%
Revenue / Employee
$1,199,808
Profits / Employee
-$28,178
Market Cap
4.40B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 499 | -18 | -3.48% |
| Dec 31, 2023 | 517 | 33 | 6.82% |
| Dec 31, 2022 | 484 | -12 | -2.42% |
| Dec 31, 2021 | 496 | 13 | 2.69% |
| Dec 31, 2020 | 483 | -101 | -17.29% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
FOLD News
- 3 days ago - Amicus Therapeutics Investment Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amicus Therapeutics, Inc. - FOLD - Business Wire
- 7 days ago - BioMarin: Amicus Buyout Sparks My Enthusiasm - Seeking Alpha
- 10 days ago - BioMarin is Buying a Rare-Disease Biotech for Nearly $5 Billion. The Stock Is Jumping. - Barrons
- 10 days ago - BioMarin to Buy Amicus Therapeutics for $4.8 Billion - WSJ
- 10 days ago - BioMarin to acquire Amicus Therapeutics for $4.8 Billion - Reuters
- 10 days ago - BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook - PRNewsWire
- 6 weeks ago - Amicus Therapeutics: Moving Towards Consistent Profitability - Seeking Alpha
- 7 weeks ago - Amicus Therapeutics, Inc. (FOLD) Presents at UBS Global Healthcare Conference 2025 Transcript - Seeking Alpha